Your browser doesn't support javascript.
loading
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Yardley, D A; Coleman, R; Conte, P; Cortes, J; Brufsky, A; Shtivelband, M; Young, R; Bengala, C; Ali, H; Eakel, J; Schneeweiss, A; de la Cruz-Merino, L; Wilks, S; O'Shaughnessy, J; Glück, S; Li, H; Miller, J; Barton, D; Harbeck, N.
Afiliação
  • Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Medical Oncology, Nashville, USA. Electronic address: dyardley@tnonc.com.
  • Coleman R; Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield, Sheffield, UK.
  • Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova and Medical Oncology 2, Istituto Oncologico Veneto, Padova, Italy.
  • Cortes J; Medical Oncology, Ramon y Cajal University Hospital, Madrid; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Brufsky A; Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA.
  • Shtivelband M; Medical Oncology, Ironwood Physicians, PC, Chandler, USA.
  • Young R; Medical Oncology, The Center for Cancer and Blood Disorders, Fort Worth, USA.
  • Bengala C; Medical Oncology, Misericordia General Hospital, Grosseto, Italy.
  • Ali H; Medical Oncology, Henry Ford Health System, Detroit, USA.
  • Eakel J; Hematology and Oncology, Florida Cancer Specialists, Sarasota, USA.
  • Schneeweiss A; Gynecology and Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • de la Cruz-Merino L; Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Wilks S; Hematology and Medical Oncology, Texas Oncology, San Antonio, USA.
  • O'Shaughnessy J; Hematology, Medical Oncology, Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, USA.
  • Glück S; GMA Early Assets, Celgene Corporation, Summit, USA.
  • Li H; Department of Biostatistics, Celgene Corporation, Summit, USA.
  • Miller J; Clinical Research and Development, Hematology/Oncology, Celgene Corporation, Summit, USA.
  • Barton D; Clinical Research and Development, Hematology/Oncology, Celgene Corporation, Summit, USA.
  • Harbeck N; Breast Cancer Center, University of Munich, Munich, Germany.
Ann Oncol ; 29(8): 1763-1770, 2018 08 01.
Article em En | MEDLINE | ID: mdl-29878040
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article